icon-folder.gif   Conference Reports for NATAP  
 
  AASLD
60th Annual Meeting of the American Association for the Study of Liver Diseases
Boston, MA, Hynes Convention Center
October 30-November 3, 2009
Back grey_arrow_rt.gif
 
 
 
Safety, Tolerability, Pharmacokinetics and Antiviral Activity following Single- and Multiple-Dose Administration of BMS- 650032, a Novel HCV NS3 Inhibitor, in Subjects with Chronic Genotype 1 HCV Infection
 
 
  Reported by Jules Levin
AASLD Nov 3 2009, Boston, MA
 
C. Pasquinelli, T. Eley, C. Villegas, K. Sandy, E. Mathias, P. Wendelburg, S. Liao, F. McPhee, P. Scola, L. Sun, T Marbury, E Lawitz, P. Goldwater, M. Rodriguez-Torres, M. DeMicco, M. Ababa, D. Wright, M. Charlton, W. Kraft, J-C, Lopez-Talavera, DM. Grasela

add.gif

image002.gif

image004.gif

image006.gif

image008.gif

image010.gif

image012.gif

image014.gif

image016.gif

image018.gif

image020.gif